ReviewFrontiers in artificial intelligence2026
AI-assisted multimodal data integration for precision oncology.
Review in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complexity of data pertaining to patients diagnosed with cancer requires a shift from fragmented, unimodal diagnostics towards multimodal artificial intelligence (MAI) in order to achieve true precision oncology. In this literature review we examined the landscape of unimodal data modalities used in oncological practice including clinical records, multi-scale imaging (radiology and histopathology), and multi-omics signatures, alongside a critical comparison of the deep-learning architectures and integrative frameworks used to combine these data sources into advanced predictive models. By using fusion strategies (early, late, intermediate, and hybrid), MAI models are able to bridge the gap between genotype and phenotype, uncovering biological interactions that remain invisible to single-modality analysis. Current applications demonstrate significant improvements in diagnostic sensitivity, automated tumor grading, and the prediction of complex clinical outcomes, such as immunotherapy response and overall survival, referencing leading-edge tools and frameworks currently used or in active research. However, the transition from research to clinical practice is hindered by limitations such as data fragmentation, demographic biases, limited model explainability, and evolving regulatory requirements. We further outline emerging directions, including multimodal foundation models, large language models, and retrieval-augmented, agent-based systems. We concluded that the convergence of multimodal data streams and biologically informed AI represents the essential step for the next generation of personalized cancer care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.